Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7376181 | 0.84 | MAPT (0.45) | MAPK1MAPTPTGDR2KMT2AMEN1 | |
| SCHEMBL4214280 | 0.80 | DGAT1 (0.58) | MAPK1MAPTPOLBDGAT1AKR1C3 | |
| SCHEMBL2989871 | 0.79 | HPGD (0.47) | MAPTPOLBDGAT1AKR1C3LTA4H | |
| SCHEMBL12629468 | 0.78 | LTA4H (0.36) | MAPTPTPN1LTA4HKMT2AMEN1 | |
| SCHEMBL907865 | 0.78 | MAPK14 (0.46) | HPGDALDH1A1HTT | |
| SCHEMBL5235158 | 0.78 | AKR1C3 (0.57) | MAPK1HSD17B10MAPTPTGDR2POLB | |
| SCHEMBL5235450 | 0.78 | AKR1C3 (0.57) | MAPK1HSD17B10MAPTPTGDR2POLB | |
| Bromide SCHEMBL3619165 | 0.77 | MAPK14 (0.45) | KMT2AHPGDMEN1ALDH1A1HTT | |
| SCHEMBL30494732 | 0.76 | CYP1A2 (0.67) | MAPTPOLBKMT2AHPGDMEN1 | |
| SCHEMBL17193968 | 0.76 | CYP1A2 (0.67) | MAPTPOLBKMT2AHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009515-A1 | Process and intermediates for preparing escitalopram | TORCAN CHEMICAL LTD (CA) | 2006-01-12 | — | — | US | claimed |
| EP-1495013-A1 | PROCESS AND INTERMEDIATES FOR PREPARING ESCITALOPRAM | TORCAN CHEMICAL Ltd (CA) | 2005-01-12 | — | — | EP | claimed |
| WO-2003087081-A1 | PROCESS AND INTERMEDIATES FOR PREPARING ESCITALOPRAM | TORCAN CHEMICAL LTD. (CA) | 2003-10-23 | — | — | WO | claimed |
| WO-2008157271-A1 | DEUTERIUM-ENRICHED ESCITALOPRAM | PROTIA LLC (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080312318-A1 | DEUTERIUM-ENRICHED ESCITALOPRAM | PROTIA, LLC (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312318-A1 | DEUTERIUM-ENRICHED ESCITALOPRAM | PROTIA, LLC (US) | 2008-12-18 | — | — | US | disclosed |
| US-7411077-B2 | Process for the preparation of a cyano-isobenzofuran | ADORKEN TECHNOLOGY SPA (IT) | 2008-08-12 | — | — | US | disclosed |
| US-20060183925-A1 | Process for the preparation of a cyano-isobenzofuran | ADORKEM TECHNOLOGY SPA | 2006-08-17 | — | — | US | disclosed |
| CN-1761658-A | Process for the preparation of a cyano-isobenzofuran | ADORKEM TECHNOLOGY SPA (IT) | 2006-04-19 | — | — | CN | disclosed |
| US-20060009515-A1 | Process and intermediates for preparing escitalopram | TORCAN CHEMICAL LTD (CA) | 2006-01-12 | — | — | US | disclosed |
| EP-1601662-A1 | PROCESS FOR THE PREPARATION OF A CYANO-ISOBENZOFURAN | Adorkem Technology SpA (IT) | 2005-12-07 | — | — | EP | disclosed |
| EP-1495013-A1 | PROCESS AND INTERMEDIATES FOR PREPARING ESCITALOPRAM | TORCAN CHEMICAL Ltd (CA) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004094399-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CITALOPRAM HYDROBROMIDE | NATCO PHARMA LTD (IN) | 2004-11-04 | — | — | WO | disclosed |
| US-6812355-B2 | INVOLVING TWO SUCCESSIVE GRIGNARD REACTIONS; EMPLOYING LEWIS ACID TO REDUCING BY-PRODUCT FORMATION | SEKHSARIA CHEMICALS LIMITED (IN) | 2004-11-02 | — | — | US | disclosed |
| WO-2004080988-A1 | PROCESS FOR THE PREPARATION OF A CYANO-ISOBENZOFURAN | ADORKEM TECHNOLOGY SPA (IT) | 2004-09-23 | — | — | WO | disclosed |
| US-20040077870-A1 | PROCESS FOR THE MANUFACTURE OF CITALOPRAM HYDROBROMIDE FROM 5-BROMOPHTHALIDE | SEKHSARIA CHEMICALS LIMITED | 2004-04-22 | — | — | US | disclosed |
| WO-2003087081-A1 | PROCESS AND INTERMEDIATES FOR PREPARING ESCITALOPRAM | TORCAN CHEMICAL LTD. (CA) | 2003-10-23 | — | — | WO | disclosed |
| EP-1288211-A1 | Improved process for the manufacture of citalopram hydrobromide from 5-bromophthalide | Sekhsaria Chemicals Ltd. (IN) | 2003-03-05 | — | — | EP | disclosed |
| US-4136193-A | ANTI-DEPRESSIVE SUBSTITUTED 1-DIMETHYLAMINOPROPYL-1-PHENYL PHTHALANS | KEFALAS A/S (DK) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312318-A1 | DEUTERIUM-ENRICHED ESCITALOPRAM | SLC6A4, SLC6A3, SLC6A2 | MAPK1 3684/4885HSD17B10 91/4885MAPT 1042/4885 |
| US-20040077870-A1 | PROCESS FOR THE MANUFACTURE OF CITALOPRAM HYDROBROMIDE FROM 5-BROMOPHTHALIDE | PBRM1, TPH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAPK1 1818/4885HSD17B10 666/4885MAPT 306/4885 |
| US-20060183925-A1 | Process for the preparation of a cyano-isobenzofuran | HTR1F, CYP4F12, CYP4F3 | MAPK1 3557/4885HSD17B10 1266/4885MAPT 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.